Dyslipidaemia in diabetes

Red Flags

Diabetes with established ASCVD and LDL-C above goal on maximally tolerated statin — add ezetimibe; PCSK9 inhibitor if not at <55 mg/dL^[1]
Triglycerides ≥1000 mg/dL with diabetes — risk of acute pancreatitis; urgent fibrate plus lifestyle, glycaemic control^[1]
Diabetes with familial hypercholesterolaemia features (LDL-C ≥190, tendon xanthomas, family history of premature CAD) — high-intensity statin and family cascade screening^[1]
Statin myopathy with diabetes (severe muscle symptoms with CK >5× ULN) — pause statin; investigate; switch class or use ezetimibe / bempedoic acid alternative^[1]

First-line treatment

Interventions

Lifestyle modification with diabetes focus^[1]
Mediterranean-style diet emphasising plant fats, oily fish; weight reduction 5–10% if overweight; ≥150 min/week aerobic activity; smoking cessation; alcohol moderation; medical nutrition therapy

First-line drug therapy

Drug	Class	Adult	Paediatric	Notes
Atorvastatin^[1]	HMG-CoA reductase inhibitor (high-intensity)	40–80 mg PO once daily for high-risk; 10–20 mg moderate-intensity for primary prevention without other risk	—	First-line for all adults with diabetes age ≥40 regardless of LDL-C; LDL-C goal <55 mg/dL very-high-risk ASCVD, <70 high-risk
Rosuvastatin^[1]	HMG-CoA reductase inhibitor	20–40 mg PO daily (high-intensity); 5–10 mg moderate	—	Alternative; preferred in renal impairment (less hepatic metabolism)
Ezetimibe^[1]	Cholesterol absorption inhibitor	10 mg PO once daily	—	Add when statin alone insufficient; ~20% additional LDL-C reduction; combined statin + ezetimibe offers similar LDL-C lowering with less statin
Fenofibrate^[1]	Fibrate	145–160 mg PO once daily	—	For severe hypertriglyceridaemia (TG ≥500); reduces pancreatitis risk; modest benefit on dual-dyslipidaemia in T2DM (FIELD subgroup)
Icosapent ethyl (high-dose EPA)^[1]	Omega-3 fatty acid (purified EPA)	2 g PO BD with meals	—	Add for diabetes with TG 135–500 on optimal statin; reduces cardiovascular events per REDUCE-IT
Evolocumab or alirocumab (PCSK9 inhibitors)^[1]	Monoclonal antibody (anti-PCSK9)	Evolocumab 140 mg SC every 2 weeks OR 420 mg SC monthly; alirocumab 75–150 mg SC every 2 weeks	—	For very-high-risk diabetes ASCVD not at LDL-C goal on maximally tolerated statin + ezetimibe

Atorvastatin^[1]

HMG-CoA reductase inhibitor (high-intensity)

Adult: 40–80 mg PO once daily for high-risk; 10–20 mg moderate-intensity for primary prevention without other risk
Paediatric: —

First-line for all adults with diabetes age ≥40 regardless of LDL-C; LDL-C goal <55 mg/dL very-high-risk ASCVD, <70 high-risk

Rosuvastatin^[1]

HMG-CoA reductase inhibitor

Adult: 20–40 mg PO daily (high-intensity); 5–10 mg moderate
Paediatric: —

Alternative; preferred in renal impairment (less hepatic metabolism)

Ezetimibe^[1]

Cholesterol absorption inhibitor

Adult: 10 mg PO once daily
Paediatric: —

Add when statin alone insufficient; ~20% additional LDL-C reduction; combined statin + ezetimibe offers similar LDL-C lowering with less statin

Fenofibrate^[1]

Fibrate

Adult: 145–160 mg PO once daily
Paediatric: —

For severe hypertriglyceridaemia (TG ≥500); reduces pancreatitis risk; modest benefit on dual-dyslipidaemia in T2DM (FIELD subgroup)

Icosapent ethyl (high-dose EPA)^[1]

Omega-3 fatty acid (purified EPA)

Adult: 2 g PO BD with meals
Paediatric: —

Add for diabetes with TG 135–500 on optimal statin; reduces cardiovascular events per REDUCE-IT

Evolocumab or alirocumab (PCSK9 inhibitors)^[1]

Monoclonal antibody (anti-PCSK9)

Adult: Evolocumab 140 mg SC every 2 weeks OR 420 mg SC monthly; alirocumab 75–150 mg SC every 2 weeks
Paediatric: —

For very-high-risk diabetes ASCVD not at LDL-C goal on maximally tolerated statin + ezetimibe

Safety-net

Statins are taken lifelong even if blood tests look good — they reduce heart attack and stroke independent of cholesterol level alone^[1]
Mild muscle aches are common; severe muscle pain or dark urine — pause statin and seek care^[1]
Triglycerides above 500 mg/dL with abdominal pain — call emergency services (pancreatitis risk)^[1]

Referral criteria

Triglycerides ≥1000 mg/dL with abdominal painEmergency department for acute pancreatitis evaluation^[1]
Suspected familial hypercholesterolaemia in diabetes (LDL-C ≥190, tendon xanthomas, premature CAD family history)Lipid clinic for genetic testing and family cascade screening^[1]
Diabetes with established ASCVD not at LDL-C goal <55 mg/dL on maximally tolerated statin + ezetimibeLipid clinic / cardiology for PCSK9 inhibitor^[1]
Statin intolerance with multiple statinsLipid clinic for bempedoic acid, ezetimibe, or PCSK9 inhibitor alternatives^[1]

Clinical summary

Diabetes-specific dyslipidaemia management — small dense LDL pattern, atherogenic lipid triad; high-intensity statin plus combination therapy for very-high-risk.

References

1.RSSDI Consensus Recommendations for Dyslipidemia Management in Diabetes Mellitus (2022); ADA Standards of Care 2026 (2022)